Development and Validation of New UV Spectrophotometric Methods for Simultaneous Estimation of Alcaftadine in Combination with Ketorolac Tromethamine in a Pharmaceutical Dosage Form and Statistical Analysis using Analysis of Variance
Abstract
Alcaftadine and Ketorolac tromethamine combination is newly introduced in the market for the treatment of conjunctivitis. Hence, it is essential to develop a rapid, accurate, sensitive and precise method (in accordance with ICH guidelines) to estimate drugs. Three simple and cost-effective UV-spectrophotometric methods (First-order derivative (A), Dual Wavelength (B) and Q- absorbance ratio method (C) have been developed for simultaneous estimation of Alcaftadine and Ketorolac tromethamine in their pharmaceutical dosage form and statistical comparison using analysis of variance (ANOVA). Method (A) is based on the first-order derivative spectrophotometric method, in which zero-crossing points (ZCP) for Alcaftadine is 281.50 nm and Ketorolac tromethamine is 268 nm. Linearity was found in the 4–14 µg/mL range for Alcaftadine and 6.4–22.4 µg/mL for Ketorolac tromethamine using methanol as a common solvent. Method (B) is based on the principle of the dual-wavelength method using absorbance difference at 336 and 299.50 nm for Alcaftadine; 268 and 293.50 nm for Ketorolac tromethamine. Method (C) is constructed on Q-absorbance ratio method where the iso-absorptive point was obtained at 296 nm and the max selected was of Alcaftadine 282 nm. The accuracy, precision, Limit of Detection (LOD), and Limit of Quantification (LOQ) of methods were determined and validated. All the developed methods showed good reproducibility and recovery with % RSD <2. These three methods developed were compared using the statistical method one-way ANOVA, and the fcal value was found to be less than ftab value, indicating that there is no significant difference in the assay results of the three methods. All three methods were found to be rapid, specific, precise, and accurate and found no interferences from the excipients, so it can be used for routine investigation of both drugs in quality control laboratories.Keywords:
Alcaftadine, ANOVA, Dual-wavelength, First-order derivative, Ketorolac tromethamine, Q-Absorbance, ValidationReferences
1. Bohets H, McGowan C, Mannens G, Schroeder N, Edwards Swanson K, A Clinical Pharmacology of Alcaftadine, a novel antihistamine for the prevention of allergic Conjunctivitis, Journal of Ocular Pharmacology and Therapeutics, 2011; 27:187-195.
2. Helms RA, Quan DJ, Herfindal EJ and Gourely DR. Therapeutics drug and disease management;8th Edn.Published by Lippincott Williams and Wilkins; Untied state of America; 2006.
3. Greiner JV, Edwards-Swanson K, Ingerman A, Evaluation of Alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and Olopatadine 0.1%, Clinical Ophthalmology, 2011; 5:87-93.
4. "Drug profile of Alcaftadine", accessed on September 2019. https://pubchem.ncbi.nlm.nih.gov/compound/Alcaftadine
5. "Drug profile of Ketorolac tromethamine", accessed on September 2019, https://pubchem.ncbi.nlm.nih.gov/compound/Ketorolac
6. Mishra PR, Satone D, Mesharm DB, Patel N, Development and validation of UV- spectroscopic methods for the estimation of Alcaftadine in bulk and its ophthalmic dosage form, FS Journal of Pharmacy Research, 2015;4:14-18.
7. Mishra PR, Inamdar P, Jamdar P, Patel N, Rohit M, Meshram DB, Development and validation of UV-spectrophotometry and the first-order derivative using the area under curve method for the determination of Alcaftadine in bulk and its ophthalmic dosage form, FS Journal of Pharmacy Research, 2015;4:9-13.
8. Mishra PR, Satone D, Mesharm DB, Patel N, Development and validation of HPLC method for the determination of Alcaftadine in bulk drug and its ophthalmic solution. Journal of chromatography and separation, 2015;7(1):1-4.
9. Chavan BB, Jyothi VP, Kalariya PD, Srinivas R, Talluri MV, Alcaftadine: Selective separation and characterization of degradation Products by LC-QTOF-MS/MS. Chromatographia, 2018;81:631-638.
10. Patel HK, Parmar PD, Ladva BJ, Nayak BS, Method development and validation of first-order derivative spectrophotometric method for simultaneous estimation of Ketorolac tromethamine and Phenylephrine hydrochloride in their synthetic Mixture. International Journal for Pharmaceutical Research Scholars, 2015;4:200-205.
11. Kaur R, Singh S, Hassan A, Jalhan S, Jain UK, Development and validation of UV spectrophotometric method for the estimation of Ketorolac tromethamine in bulk drug. World Journal of Pharmacy and Pharmaceutical Sciences, 2016;5:1792-1799.
12. Tandel A, Shah P, Rajput S, Simultaneous estimation of Phenylephrine hydrochloride and Ketorolac tromethamine using UV spectrophotometric and HPLC methods, American Journal of Pharmaceutical Research, 2017;7:7381-7389.
13. Nayak S, Srinivasa U, Kamath SK, Shabaraya AR.Zero-order and first-order derivative spectroscopic method for simultaneous estimation of Moxifloxacin hydrochloride and Ketorolac tromethamine in simulated tear fluid, PharmaTutor, 2016; 4: 43-47.
14. Begum S, Bharathi D, Vaddepally L, Tulja R. A validated RP-HPLC method for simultaneous estimation of Moxifloxacin hydrochloride and Ketorolac tromethamine in ophthalmic dosage form, Der Pharmacia Lettre, 2014; 6:335-341.
15. El Yazbi F, Hassan EM, Khamis EF, Marwa AR, and Mohamed MH, Development and validation of a High-performance thin-layer chromatographic method for the simultaneous determination of two binary mixtures containing Ketorolac tromethamine with Phenylephrine hydrochloride and with Febuxostat, Journal of Chromatographic Science, 2016;54:819-828.
16. Uddin M, Amin MA, Mijjan N, Das S, Stability indicating UPLC method for the degradation study of Ketorolac Tromethamine, Indonesian Journal of Pharmaceutical Science and Technology, 2019;6:11-26.
17. Manwar JV, Patil SS, Bhalerao CA, Mandpe SR, Kumbhar DD. Experimental design approach for chromatographic determination of Ketorolac tromethamine from bulk drug and tablet Formulation, International Journal of Pharmaceutics, 2017;3:1-10.
18. ICH, Q2 (R1), Harmonized tripartite guideline, validation of analytical procedures: text and methodology, International Conference on Harmonization ICH, Geneva, Nov 2005.
Published
Abstract Display: 0
PDF Downloads: 0